HealthDay News — For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual ...
US-based patients with idiopathic pulmonary fibrosis (IPF) had a slower decline in forced vital capacity (FVC) when they received nerandomilast (Jascayd; Boehringer Ingelheim) compared with placebo, a ...
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for ...
Nerandomilast significantly slowed lung function decline in patients with IPF, with the 18 mg dose showing a 68.8 mL FVC decline reduction compared with placebo. The trial included 1177 patients, 78% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback